Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
Taltz® (ixekizumab): Dosage Regimen for Plaque Psoriasis in Adults
160 mg week 0; 80 mg week 2, 4, 6, 8, 10, 12; 80 mg every 4 weeks thereafter.
The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) at Weeks 2, 4, 6, 8, 10, and 12, then maintenance dosing of 80 mg (one injection) every 4 weeks.1
Dosing in specific patient populations
In elderly patients (≥ 65 years) is no dose adjustment required. There is limited information in subjects aged ≥ 75 years.1
Ixekizumab has not been studied in patients with renal or hepatic impairment. No dose recommendations can be made.1
Discontinuation of treatment
Consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment. Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.1
Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Ixekizumab is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Ixekizumab is indicated.1
1. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: June 05, 2019